annb0t
Top 20
Incannex Healthcare Limited (NASDAQ: IXHL) has completed a preliminary analysis of data from its Phase 2 trial of a cannabinoid combination product, IHL-42X, for obstructive sleep apnoea (OSA).
The clinical trial assessed three doses of IHL-42X at reducing the apnoea hypopnoea index (AHI), the main diagnostic and monitoring criteria for OSA, compared to placebo. For all IHL-42X treatment periods (using low, mid, and high doses), the average AHI was 23.81, a 44.4 % reduction from the baseline sc...
>>> Read more: Incannex's Cannabinoid Combo Product Reduces AHI In Sleep Apnea Patients
The clinical trial assessed three doses of IHL-42X at reducing the apnoea hypopnoea index (AHI), the main diagnostic and monitoring criteria for OSA, compared to placebo. For all IHL-42X treatment periods (using low, mid, and high doses), the average AHI was 23.81, a 44.4 % reduction from the baseline sc...
>>> Read more: Incannex's Cannabinoid Combo Product Reduces AHI In Sleep Apnea Patients
